Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | POLG | P54098 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129336 | 0.98 | DUT (0.52) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL475343 | 0.92 | DUT (0.52) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL21647246 | 0.88 | DUT (0.48) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL150273 | 0.86 | DUT (0.52) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL7745800 | 0.86 | DUT (0.55) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8441083 | 0.86 | DUT (0.52) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL7628981 | 0.86 | DUT (0.45) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL16670190 | 0.84 | DUT (0.51) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8439797 | 0.84 | DUT (0.51) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL11686095 | 0.84 | DUT (0.49) | DUTP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538151-B1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INST BIOMEDICAL RES (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230051644-A1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-16 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| US-11453858-B2 | Human plasma-like medium | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4023299-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | Nucana PLC (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3447061-B1 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHORAMIDATE DERIVATIVE OF 5-FLUORO-2'-DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-10993957-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2021-05-04 | — | — | US | disclosed |
| WO-2006128463-A2 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT | DAKO DENMARK A/S (DK) | 2006-12-07 | — | — | WO | disclosed |
| US-20060253263-A1 | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy | MESHKIN BRIAN J | 2006-11-09 | — | — | US | disclosed |
| US-20050191691-A1 | Gene sequence variances in genes related to folate metabolism having utility in determining the treatment of disease | VARIAGENICS, INC., A DELAWARE CORPORATION | 2005-09-01 | — | — | US | disclosed |
| US-20050112680-A1 | Gene sequence variances in genes related to folate metabolism having utility in determining the treatment of disease | VARIAGENICS, A DELWARE CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-6759200-B1 | FOR ESTABLISHING DIAGNOSTIC TESTS USEFUL FOR IMPROVING THE DEVELOPMENT AND USE OF PHARMACEUTICAL PRODUCTS IN CLINICAL SETTING | NUVELO, INC. | 2004-07-06 | — | — | US | disclosed |
| US-6664062-B1 | Determining if a sample comprises a nucleic acid molecule that hybridizes to a probe comprising a specific nucleotide sequence | NUVELO, INC. | 2003-12-16 | — | — | US | disclosed |
| US-6537759-B1 | Identification of gene sequence variances useful in therapeutics; optimizing the efficacy and safety of drugs; diagnostic tests for drug development | VARIAGENICS, INC. | 2003-03-25 | — | — | US | disclosed |
| US-20020039990-A1 | Gene sequence variances in genes related to folate metabolism having utility in determining the treatment of disease | VARIAGENICS, INC. | 2002-04-04 | — | — | US | disclosed |
| EP-1100964-A1 | GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | Variagenics, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000004194-A1 | GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | VARIAGENICS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | DUT 10/4885P2RY2 773/4885P2RY4 1067/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | DUT 10/4885P2RY2 767/4885P2RY4 1070/4885 |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | DUT 9/4885P2RY2 707/4885P2RY4 1020/4885 |
| US-10993957-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | DUT 11/4885P2RY2 870/4885P2RY4 1118/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | DUT 9/4885P2RY2 717/4885P2RY4 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.